Sanofi SA vs Thomson Reuters Corp — how do they compare? Sanofi SA trades at $44.05 (market cap $104.83B), while Thomson Reuters Corp trades at $90.98 (market cap $41.28B). The key difference: Sanofi SA is far larger — about 2.5× Thomson Reuters Corp's market cap, and Sanofi SA pays the higher dividend (5.5%). Which is the better fit depends on your goals.
| SNY | TRI | |
|---|---|---|
Market Cap | $104.83B | $41.28B |
Sector | Health | Industrials |
52-Week High | $52.34 | $205.54 |
52-Week Low | $41.33 | $76.55 |
Enterprise Value | $121.32B | $43.24B |
Dividend Yield | 5.5% | 2.75% |
Trailing returns across standard periods
Latest headlines on both assets
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →Thomson Reuters is the result of the $17.6 billion megamerger of Canada's Thomson and the United Kingdom's Reuters Group in 2008 and the 2018 carve-out of its finance and risk business, Refinitiv, in which it holds a 45% stake. In 2019, the company agreed to exchange its 45% stake in Refinitiv for a 15% stake in LSE, which closed in early 2021. Since the divestiture, the company is more concentrated on selling its flagship legal data and software, Westlaw, and its tax accounting software, Onesource. Reuters sees roughly 80% of revenue and 70% of expenses attributed to the United States, while the remainder (largely through the global print and Reuters News segments) is distributed across Latin America, Europe, the Middle East, Africa, and Asia-Pacific.
Read more on TRI →